BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ruilope LM, Tamargo J, Ruiz-Hurtado G. Renin-angiotensin system inhibitors in the COVID-19 pandemic: consequences of antihypertensive drugs. Eur Heart J 2020;41:2067-9. [PMID: 32498078 DOI: 10.1093/eurheartj/ehaa487] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Boari GEM, Chiarini G, Bonetti S, Malerba P, Bianco G, Faustini C, Braglia-Orlandini F, Turini D, Guarinoni V, Saottini M, Viola S, Ferrari-Toninelli G, Pasini G, Mascadri C, Bonzi B, Desenzani P, Tusi C, Zanotti E, Nardin M, Rizzoni D. Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective cohort study. Biosci Rep 2020;40:BSR20203455. [PMID: 33201172 DOI: 10.1042/BSR20203455] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
2 Moghnieh R, Abdallah D, Bizri AR. COVID-19: Second Wave or Multiple Peaks, Natural Herd Immunity or Vaccine - We Should be Prepared. Disaster Med Public Health Prep 2020;:1-8. [PMID: 32907693 DOI: 10.1017/dmp.2020.349] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
3 Lüscher TF. The saga continues: is COVID-19 a cardiopulmonary disease? Eur Heart J 2020;41:2041-4. [PMID: 33216882 DOI: 10.1093/eurheartj/ehaa502] [Reference Citation Analysis]
4 Feldman DI, Wu KC, Hays AG, Marvel FA, Martin SS, Blumenthal RS, Sharma G. The Johns Hopkins Ciccarone Center's expanded 'ABC's approach to highlight 2020 updates in cardiovascular disease prevention. Am J Prev Cardiol 2021;6:100181. [PMID: 34327502 DOI: 10.1016/j.ajpc.2021.100181] [Reference Citation Analysis]
5 Crea F. European Society of Cardiology guidance for the management of cardiovascular disease during the pandemic and a focus on long COVID. European Heart Journal 2022;43:1017-21. [DOI: 10.1093/eurheartj/ehac087] [Reference Citation Analysis]
6 Estruch R, Ruilope LM, Cosentino F. The year in cardiovascular medicine 2020: epidemiology and prevention. Eur Heart J 2021;42:813-21. [PMID: 33388753 DOI: 10.1093/eurheartj/ehaa1062] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 El-Hanboushy S, Marzouk HM, Fayez YM, Abdelkawy M, Lotfy HM. Eco-friendly spectrophotometric evaluation of triple-combination therapies in the treatment strategy of patients suffering from hypertension during coronavirus pandemic - Spectralprint recognition study. Spectrochim Acta A Mol Biomol Spectrosc 2022;280:121523. [PMID: 35759933 DOI: 10.1016/j.saa.2022.121523] [Reference Citation Analysis]
8 Ferrario CM, Ahmad S, Groban L. Twenty years of progress in angiotensin converting enzyme 2 and its link to SARS-CoV-2 disease. Clin Sci (Lond) 2020;134:2645-64. [PMID: 33063823 DOI: 10.1042/CS20200901] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Orozco-Beltrán D, Brotons Cuixart C, Alemán Sánchez JJ, Banegas Banegas JR, Cebrián-Cuenca AM, Gil Guillen VF, Martín Rioboó E, Navarro Pérez J. [Cardiovascular preventive recommendations. PAPPS 2020 update]. Aten Primaria 2020;52 Suppl 2:5-31. [PMID: 33388118 DOI: 10.1016/j.aprim.2020.08.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Haybar H, Maniati M, Saki N, Zayeri ZD. COVID-19: imbalance of multiple systems during infection and importance of therapeutic choice and dosing of cardiac and anti-coagulant therapies. Mol Biol Rep 2021;48:2917-28. [PMID: 33837899 DOI: 10.1007/s11033-021-06333-w] [Reference Citation Analysis]